Epkinly (Epcoritamab) how to use: Uses, Dosage, Side Effects, Contraindications

(4:7)

Epcoritamab (Epkinly), a novel bispecific antibody to target cancer cells

(3:32)

Epkinly (epcoritamab-bysp)- refractory diffuse large B-cell lymphoma (DLBCL)

(1:53)

Dr Nowakowski on the FDA Approval of Epcoritamab in R/R Follicular Lymphoma

(1:6)

Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD

(5:57)

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma

(3:2)

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

(5:36)

EPCORE NHL-1 subgroup analyses: epcoritamab monotherapy in patients with R/R LBCL

(1:46)

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma

(2:30)

Epcoritamab + R-CHOP overcomes high total metabolic tumor volume in high-risk large B-cell lymphoma

(36)

New DLBCL Clinical Trial: Epcoritamab for Diffuse Large B-Cell Lymphoma

(1:9)

Epkinly Clinical Pearl

(8:41)

Subcutaneous epcoritamab in R/R B-cell NHL

(2:42)

Advantages of bispecific antibodies for lymphoma: mosunetuzumab, epcoritamab \u0026 glofitamab

(1:31)

Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Epcoritamab - Blood Cancers OncTalk 2023

(6:6)

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma - Blood Cancers OncTalk 2023

(2:47)

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab \u0026 more

(2:8)

Comparative effectiveness of epcoritamab versus real-world usual care in R/R follicular lymphoma

(2:26)

Genmab and AbbVie Present New Epcoritamab Data at EHA 2023

(8:)

Joshua Brody on Epcoritamab Immunotherapy for DLBCL | ASCO 2024

(3:13)